Key result
Platelet aggregometry assays provide a versatile in vitro method to evaluate the effects of platelet agonists and antiplatelet compounds on human platelet function.
This paper provides a detailed methodology for performing platelet aggregometry assays to evaluate platelet function and the effects of various agonists and antiplatelet agents.
Answers are grounded in this paper and cite their sources.
In vitro platelet findings warrant no clinical change yet; leaves open need for in vivo validation of antiplatelet effects.
Platelet aggregometry assays are generally used for the analysis of platelet function but can also be adapted for further research and therapy focused applications. This method describes the procedures for the preparation of human platelet-rich plasma (PRP) and platelet-poor plasma (PPP) for the assessment of human platelet aggregation induced by agonists such as platelet-activating factor (PAF), thrombin, collagen, adenosine diphosphate (ADP), arachidonic acid, etc.•This method can be applied in vitro to evaluate the aggregatory effects of these agonists and to assess the antiaggregatory effects of several bioactive antiplatelet agents (compounds of natural or pharmacological origin) in human PRP.•This versatile method can be used in both basic and clinical research for the assessment of platelet aggregation (a major cardiovascular risk factor), platelet agonists, and inhibitors, in physiological or pathological conditions.•This method can be adapted to assess platelet activity in postprandial and intervention studies ex vivo.
No takes yet. Share an insight, caveat, or question.
Τσούπρας et al. (2018) studied this question. Platelet aggregometry assay was evaluated. Platelet aggregometry assays provide a versatile in vitro method to evaluate the effects of platelet agonists and antiplatelet compounds on human platelet function.
Synapse has enriched 10 related papers. Consider them for comparative context: